Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $84.92 USD
Change Today -0.08 / -0.09%
Volume 1.4M
ENDP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 5:20 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Key Developments

Endo International plc Appoints Paul Campanelli to Lead Generics Business and Join Executive Leadership Team

Endo International plc and Par Pharmaceutical Holdings Inc. announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. Par CEO Paul Campanelli to join Endo to lead generics business and join executive leadership team.

Endo International plc, Par Pharmaceutical Holdings, Inc. - M&A Call

To discuss the acquisition of Par Pharmaceutical

Endo International Seeks Acquisitions

Endo International plc (NasdaqGS:ENDP) will consider acquisitions. Endo said it is seeking a capital structure that will allow for more acquisitions in the future.

Endo Pharmaceuticals Inc Receives U.S. Food and Drug Administration Approval for Label Update for XIAFLEX

Endo Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a label update for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord. The updated label now includes a long-term, observational study demonstrating the rate of recurrence for up to 5 years after successful treatment with XIAFLEX®, and the efficacy and safety of retreatment in patients with recurrent DC. DC is a chronic condition affecting the hand in which abnormal buildup of collagen can cause the fingers to bend and be drawn in toward the palm. It is a rare genetic condition affecting up to 7% of adults in the United States. An estimated 20% to 60% of cases may recur following treatment. The long-term, observational study (referred to as Study 4 in the product label) evaluated the recurrence of contracture and safety at Year 2 to Year 5 in patients who had received up to 8 single injections of XIAFLEX® in a previous open-label or double-blind with open-label extension study. A total of 645 patients were enrolled, of whom 30% discontinued the study. Recurrence was assessed in successfully treated joints (i.e., a reduction in contracture to 5 degrees or less 30 days after the last injection of XIAFLEX®) and was defined as an increase in joint contracture by at least 20 degree in the presence of a palpable cord, or the joint underwent medical or surgical intervention primarily to correct a new or worsening DC in that joint. Following successful treatment, the probability of remaining recurrence free was 80% at Year 2 and 50% at Year 5. The second study (referred to as Study 5 in the product label) evaluated a subset of patients from Study 4 for a\ joint that was previously successfully treated but had recurrence. Patients in this study received up to 3 injections of XIAFLEX®. Of the 91 patients eligible for the study, 52 enrolled. In the study, 65% of recurrence in the metacarpophalangeal (MP) joints (i.e., the knuckle between the hand and the finger) and 45% of recurrence in the proximal interphalangeal (PIP) joints (i.e., middle joint of a finger) achieved clinical success after retreatment. No new safety signals were identified among subjects who were retreated with XIAFLEX®.

Endo International plc Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Year Ending December 31, 2015; Announces Impairment Charges for the First Quarter of 2015

Endo International plc announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $714 million, a 52% increase compared to first quarter 2014 revenues of $471 million. Income from continuing operations was $150 million compared to a first quarter 2014 reported loss from continuing operations of $47 million. Adjusted income from continuing operations was $207 million, a 91% increase compared to first quarter 2014 adjusted income from continuing operations of $108 million. Diluted EPS from continuing operations was $0.85 compared to first quarter 2014 reported loss per share from continuing operations of $0.37. Adjusted diluted earnings per share from continuing operations was $1.17 compared to first quarter 2014 adjusted diluted earnings per share from continuing operations of $0.75. Operating income was $45.7 million compared with $21.9 million a year ago. Non-GAAP operating income was $317.6 million compared with $179.6 million a year ago. Loss from continuing operations before income tax was $16.4 million compared with $34.7 million a year ago. Non-GAAP income from continuing operations before income tax was $247.8 million compared with $138.6 million a year ago. Net loss attributable to the company was $75.7 million compared with $47.4 million a year ago. Net loss attributable to the company was $75.7 million or $0.43 per diluted share compared with $436.9 million or $3.41 per diluted share a year ago. Non-GAAP net income attributable to the company was $228.0 million or $1.29 per diluted share compared with $134.1 million or $0.92 per diluted share a year ago. Net cash used in operating activities was $89.8 million compared with $246.9 million a year ago. Purchases of property, plant and equipment, net was $17.2 million compared with $20.8 million a year ago. For the full twelve months ending December 31, 2015, the company estimates total revenue to be between $2.90 billion and $3.00 billion; reported (GAAP) diluted earnings per share (EPS) from continuing operations now expected to be between $1.70 and $1.90 compared to $2.73 and $2.93 previously; and adjusted diluted EPS from continuing operations now expected to be between $4.40 and $4.60 compared to $4.35 and $4.55 previously. The company estimates adjusted gross margin of between 64% and 65%, adjusted interest expense of approximately $310 million and adjusted effective tax rate of between 13% and 14%. The company announced asset impairment charges of $7,000,000 for the first quarter ended March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $84.92 USD -0.08

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.133.00 CHF -1.40
CR Bard Inc $171.95 USD -0.43
Edwards Lifesciences Corp $130.88 USD -0.94
Mallinckrodt PLC $127.18 USD -1.63
UCB SA €64.54 EUR +2.00
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.